Geert-Jan Mulder, MD

Geert-Jan is one of the co-founding Managing Partners at Forbion and led the firm’s investments of several portfolio companies like bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne in 2018), Promedior (sold to Roche in 2020), KaNDy Therapeutics (sold to Bayer in 2020), the sale of the TMEM-16 program by Enterprise Therapeutics (sold to Roche in 2020), Sanifit (sold to Vifor in 2021) and Mariana (sold to Novartis in 2024).

In addition to portfolio management, Geert-Jan closely works with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters, such as IND/ NDA filings, Special Protocol Assessment (SPA), Breakthrough Designation and US / EU Orphan designations for several products, also reflected by being a co-author of several Forbion and Forbion portfolio related scientific publications.

Before co-founding Forbion, Geert-Jan was an Investment Director at ABN AMRO Capital Life Sciences since 2001. Prior to that, Geert-Jan worked in the pharmaceutical industry at Byk Gulden (now Takeda) as Clinical Research Manager, where his group was responsible for design and execution of early and late stage clinical trials forming the basis for two global product registrations: Daxas® and Alvesco® in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group. Before Byk, Geert-Jan was Medical Adviser at Searle (now Pfizer) in the field of Arthritis & Pain, being involved in the clinical development of Celebrex® and its European Advocate Development.

Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.